Compare · MDLN vs NARI
MDLN vs NARI
Side-by-side comparison of Medline Inc. (MDLN) and Inari Medical Inc. (NARI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and NARI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 14.7x NARI ($3.47B).
- MDLN has hit the wire 4 times in the past 4 weeks while NARI has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 18 for NARI).
- Company
- Medline Inc.
- Inari Medical Inc.
- Price
- $38.78+3.02%
- $79.97+0.03%
- Market cap
- $50.91B
- $3.47B
- 1M return
- +7.57%
- -
- 1Y return
- -4.83%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 18
NARI
Inari Medical Inc.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It offers ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest NARI
- Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone
- SEC Form 15-12G filed by Inari Medical Inc.
- Director Warner Robert Keith closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Tu Thomas was granted 7,406 shares, closing all direct ownership in the company (SEC Form 4)
- Director Szyman Catherine M. closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Strange Kevin T closing all direct ownership in the company (SEC Form 4)
- Principal Accounting Officer Silva Karen closing all direct ownership in the company (SEC Form 4)
- Director Root Jonathan D closing all direct ownership in the company (SEC Form 4)
- Director Milder Donald B closing all direct ownership in the company (SEC Form 4)
- Director Mead Dana G Jr. closing all direct ownership in the company (SEC Form 4)